1-155235002-C-T
Position:
Variant summary
Our verdict is Likely pathogenic. Variant got 9 ACMG points: 10P and 1B. PM5PP5_Very_StrongBP4
The NM_000157.4(GBA1):c.1604G>A(p.Arg535His) variant causes a missense change involving the alteration of a non-conserved nucleotide. In-silico tool predicts a benign outcome for this variant. 12/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R535C) has been classified as Pathogenic.
Frequency
Genomes: 𝑓 0.000055 ( 0 hom., cov: 11)
Exomes 𝑓: 0.00012 ( 0 hom. )
Failed GnomAD Quality Control
Consequence
GBA1
NM_000157.4 missense
NM_000157.4 missense
Scores
2
5
12
Clinical Significance
Conservation
PhyloP100: 0.830
Genes affected
GBA1 (HGNC:4177): (glucosylceramidase beta 1) This gene encodes a lysosomal membrane protein that cleaves the beta-glucosidic linkage of glycosylceramide, an intermediate in glycolipid metabolism. Mutations in this gene cause Gaucher disease, a lysosomal storage disease characterized by an accumulation of glucocerebrosides. A related pseudogene is approximately 12 kb downstream of this gene on chromosome 1. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Jan 2010]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Likely_pathogenic. Variant got 9 ACMG points.
PM5
Other missense variant is known to change same aminoacid residue: Variant chr1-155235003-G-A is described in ClinVar as [Pathogenic]. Clinvar id is 242383.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
PP5
Variant 1-155235002-C-T is Pathogenic according to our data. Variant chr1-155235002-C-T is described in ClinVar as [Likely_pathogenic]. Clinvar id is 4311.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr1-155235002-C-T is described in Lovd as [Pathogenic]. Variant chr1-155235002-C-T is described in Lovd as [Pathogenic].
BP4
Computational evidence support a benign effect (MetaRNN=0.32971787). . Strength limited to SUPPORTING due to the PP5.
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
|---|---|---|---|---|---|---|---|
| GBA1 | NM_000157.4 | c.1604G>A | p.Arg535His | missense_variant | 11/11 | ENST00000368373.8 |
Ensembl
| Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
|---|---|---|---|---|---|---|---|---|---|
| GBA1 | ENST00000368373.8 | c.1604G>A | p.Arg535His | missense_variant | 11/11 | 1 | NM_000157.4 | P1 |
Frequencies
GnomAD3 genomes 0.0000553 AC: 5AN: 90450Hom.: 0 Cov.: 11
GnomAD3 genomes
AF:
AC:
5
AN:
90450
Hom.:
Cov.:
11
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.000182 AC: 31AN: 170078Hom.: 0 AF XY: 0.000155 AC XY: 14AN XY: 90332
GnomAD3 exomes
AF:
AC:
31
AN:
170078
Hom.:
AF XY:
AC XY:
14
AN XY:
90332
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.000118 AC: 80AN: 680418Hom.: 0 Cov.: 9 AF XY: 0.0000993 AC XY: 35AN XY: 352508
GnomAD4 exome
AF:
AC:
80
AN:
680418
Hom.:
Cov.:
9
AF XY:
AC XY:
35
AN XY:
352508
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome 0.0000553 AC: 5AN: 90450Hom.: 0 Cov.: 11 AF XY: 0.0000243 AC XY: 1AN XY: 41182
GnomAD4 genome
Data not reliable, filtered out with message: AS_VQSR
AF:
AC:
5
AN:
90450
Hom.:
Cov.:
11
AF XY:
AC XY:
1
AN XY:
41182
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
ESP6500AA
AF:
AC:
1
ESP6500EA
AF:
AC:
1
ExAC
AF:
AC:
10
ClinVar
Significance: Pathogenic/Likely pathogenic
Submissions summary: Pathogenic:18Other:1
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Gaucher disease type I Pathogenic:7
| Pathogenic, criteria provided, single submitter | clinical testing | Hadassah Hebrew University Medical Center | Jun 20, 2019 | - - |
| Pathogenic, criteria provided, single submitter | curation | Broad Center for Mendelian Genomics, Broad Institute of MIT and Harvard | Jan 22, 2020 | The p.Arg535His variant in GBA has been reported in at least 24 individuals with Gaucher Disease (PMID: 17059888, 24756352, 17427031, 20629126, 7655857, 28947706, 23430543, 8432537) and has been identified in 0.2% (22/8934) of Ashkenazi Jewish chromosomes and 0.011% (2/17404) of African chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs75822236). Although this variant has been seen in the general population, its frequency is low enough to be consistent with a recessive carrier frequency taking into consideration that the carrier frequency of GBA variants is increased in the Ashkenazi Jewish population. This variant has also been reported in ClinVar (VariationID: 4311) as pathogenic by EGL Genetic Diagnostics, Knight Diagnostic Laboratories, Counsyl, Integrated Genetics, Fulgent Genetics, and OMIM. In vitro functional studies showing the variant to result in significantly reduced CRIM specific activity provide some evidence that the p.Arg535His variant may slightly impact protein function (PMID: 16293621). However, these types of assays may not accurately represent biological function. Computational prediction tools and conservation analyses do not provide strong support for or against an impact to the protein. However, the presence of this variant in one affected homozygote and in combination with reported pathogenic variants (VariationID: 4302, 4297, 4290, 4288; PMID: 23430543, 28947706, 20629126, 17059888, 8432537) in 9 individuals with Gaucher disease increases the likelihood that the p.Arg535His variant is pathogenic. The phenotype of an individual compound heterozygous for this variant is highly specific for Gaucher disease based on beta-glucosidase levels being below the diagnostic cutoff of 8.7nmol/h/mg protein consistent with disease (PMID: 20629126). One additional pathogenic variant, resulting in a different amino acid change at the same position, p.Arg535Cys, has been reported in association with disease in ClinVar and the literature, slightly supporting that a change at this position may not be tolerated (Variation ID: 242383; PMID: 27865684, 30637984, 30764785). In summary, this variant meets criteria to be classified as pathogenic for Gaucher disease in an autosomal recessive manner based on the presence of the variant in combination with other pathogenic variants in affected individual and the presence of another pathogenic variant at the same position. ACMG/AMP Criteria applied: PM3_very-strong, PM5, PM2_supporting, PP4, PS3_supporting (Richards 2015). - |
| Pathogenic, criteria provided, single submitter | clinical testing | Victorian Clinical Genetics Services, Murdoch Childrens Research Institute | Oct 15, 2020 | Based on the classification scheme VCGS_Germline_v1.3.4, this variant is classified as Pathogenic. Following criteria are met: 0102 - Loss of function is a known mechanism of disease in this gene and is associated with Gaucher disease (OMIM). (I) 0106 - This gene is associated with autosomal recessive disease. (I) 0115 - Variants in this gene are known to have variable expressivity. Gaucher disease is associated with marked clinical variability, even within the same family (PMID: 31010158; 27735925). (I) 0200 - Variant is predicted to result in a missense amino acid change from arginine to histidine. (I) 0304 - Variant is present in gnomAD <0.01 for a recessive condition (v2) (34 heterozygotes, 0 homozygotes). (SP) 0309 - An alternative amino acid change at the same position has been observed in gnomAD (v2) (2 heterozygotes, 0 homozygotes). (I) 0504 - Same amino acid change has been observed in placental mammals. (SB) 0604 - Variant is not located in an established domain, motif, hotspot or informative constraint region. (I) 0801 - This variant has strong previous evidence of pathogenicity in unrelated individuals. This variant, also known as R496H in an alternative nomenclature, has been reported in at least 15 patients with Gaucher disease (GD) Type 1. It is often associated with a milder adult-onset GD clinical course, although some patients may experience symptoms during childhood (ClinVar; PMID: 27735925; 23430543). (SP) 1208 - Inheritance information for this variant is not currently available in this individual. (I) Legend: (SP) - Supporting pathogenic, (I) - Information, (SB) - Supporting benign - |
| Pathogenic, no assertion criteria provided | literature only | OMIM | Jun 15, 1993 | - - |
| Pathogenic, criteria provided, single submitter | clinical testing | Knight Diagnostic Laboratories, Oregon Health and Sciences University | Feb 02, 2015 | - - |
| Pathogenic, criteria provided, single submitter | clinical testing | Myriad Genetics, Inc. | Dec 19, 2019 | NM_001005741.2(GBA):c.1604G>A(R535H, aka R496H) is classified as pathogenic in the context of Gaucher disease and is associated with Type 1 form of disease. Sources cited for classification include the following: PMID 25558695, 8213821, 16293621, 84325327, 12972024, 9240741 and 7916532. Classification of NM_001005741.2(GBA):c.1604G>A(R535H, aka R496H) is based on the following criteria: This is a well-established pathogenic variant in the literature that has been observed more frequently in patients with clinical diagnoses than in healthy populations. Please note: this variant was assessed in the context of healthy population screening. - |
| Pathogenic, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Dec 06, 2018 | The p.Arg535His (also known as p.Arg496His) variant in GBA has been reported in >20 compound heterozygous individuals (majority of Ashkenazi Jewish origin) with mild forms of Gaucher disease type I (Beutler 1993, Brautbar 2003, Yang 2017). This variant is considered a mild variant, with compound heterozygotes typically presenting as asymptomatic to mild, non-neurological cases (Brautbar 2003, Yang 2017). No homozygotes have been reported, and it is hypothesized that homozygot es may be asymptomatic. This variant was also identified in 0.25% (22/8934) of A shkenazi Jewish chromosomes by gnomAD (http://gnomad.broadinstitute.org) and in ClinVar (Variation ID# 4311). In vitro functional studies support an impact on p rotein function (Liou 2006, Choy 1996). In summary, this variant meets criteria to be classified as pathogenic for autosomal recessive Gaucher disease. ACMG/AMP Criteria applied: PM3_Very Strong, PS3_Moderate, PS4_Moderate. - |
not provided Pathogenic:5
| Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Dec 11, 2019 | Published functional studies demonstrate that this variant had little or no catalytic activity (Liou et al., 2006); This variant is associated with the following publications: (PMID: 33176831, 29471591, 31589614, 32985097, 32042592, 28966932, 29842932, 27735925, 23430543, 12972024, 8432537, 18434642, 26233692, 26857292, 16148263, 22935721, 16293621, 22975760, 23699752, 23588557) - |
| Likely pathogenic, criteria provided, single submitter | clinical testing | AiLife Diagnostics, AiLife Diagnostics | Jun 10, 2021 | - - |
| Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 11, 2024 | This sequence change replaces arginine, which is basic and polar, with histidine, which is basic and polar, at codon 535 of the GBA protein (p.Arg535His). This variant is present in population databases (rs75822236, gnomAD 0.2%). This missense change has been observed in individual(s) with dementia with Lewy bodies, Gaucher disease, and/or Parkinson's disease (PMID: 8432537, 12972024, 23430543, 23588557, 23699752, 25933391, 27735925). This variant is also known as p.Arg496His or R496H. ClinVar contains an entry for this variant (Variation ID: 4311). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) has been performed at Invitae for this missense variant, however the output from this modeling did not meet the statistical confidence thresholds required to predict the impact of this variant on GBA protein function. Experimental studies have shown that this missense change affects GBA function (PMID: 16293621). For these reasons, this variant has been classified as Pathogenic. - |
| Pathogenic, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Apr 27, 2015 | - - |
| Pathogenic, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Jul 23, 2021 | - - |
Gaucher disease Pathogenic:2Other:1
| Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Jan 19, 2016 | - - |
| Pathogenic, no assertion criteria provided | clinical testing | Natera, Inc. | Mar 17, 2017 | - - |
| not provided, no classification provided | literature only | GeneReviews | - | - - |
Parkinson disease, late-onset Pathogenic:1
| Pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | May 03, 2021 | - - |
not specified Pathogenic:1
| Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Jun 23, 2022 | The p.R535H pathogenic mutation (also known as c.1604G>A and p.R496H), located in coding exon 11 of the GBA gene, results from a G to A substitution at nucleotide position 1604. The arginine at codon 535 is replaced by histidine, an amino acid with highly similar properties. In one study of 2,012 individuals screened for various autosomal recessive conditions, it was the third most common GBA alteration detected with a carrier frequency of 1 in 335 (Scott SA et al. Hum. Mutat. 2010; 31(11):1240-50). In addition, this variant has been detected on several alleles from individuals with Gaucher disease; however, specific phenotype information and/or additional mutation and phase information was not provided (Beutler E et al. Genomics 1993;15(1):203-5; Siebert M et al. JIMD Rep 2013 ; 9():7-16; Alfonso P et al. J. Hum. Genet. 2007; 52(5):391-6). This variant has also been detected in two individuals with Parkinson disease and Lewy body dementia (Chahine LM et al. JAMA Neurol 2013; 70(7):852-8; Nalls MA et al. JAMA Neurol 2013 ; 70(6):727-35). In another study which characterized basic kinetic, stability, and activator response properties of this alteration in an in vitro environment, authors concluded that this alteration has little, if any, in vitro catalytic activity (Liou B et al. J. Biol. Chem. 2006; 281(7):4242-53). Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. - |
Gaucher disease type II;C0268251:Gaucher disease type III;C0752347:Lewy body dementia;C1842704:Gaucher disease perinatal lethal;C1856476:Gaucher disease-ophthalmoplegia-cardiovascular calcification syndrome;C1961835:Gaucher disease type I;C3160718:Parkinson disease, late-onset Pathogenic:1
| Pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Dec 29, 2021 | - - |
Gaucher disease type II;C0268251:Gaucher disease type III;C1856476:Gaucher disease-ophthalmoplegia-cardiovascular calcification syndrome;C1961835:Gaucher disease type I Pathogenic:1
| Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | - | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Pathogenic
CADD
Benign
DANN
Benign
DEOGEN2
Uncertain
D;D;.;.
Eigen
Benign
Eigen_PC
Benign
FATHMM_MKL
Uncertain
D
LIST_S2
Uncertain
.;D;D;D
M_CAP
Uncertain
D
MetaRNN
Benign
T;T;T;T
MetaSVM
Benign
T
MutationAssessor
Benign
N;N;.;.
MutationTaster
Benign
A;A;A;A;A
PrimateAI
Benign
T
PROVEAN
Benign
N;N;N;N
REVEL
Uncertain
Sift
Benign
T;T;T;D
Sift4G
Benign
T;T;T;T
Polyphen
P;P;.;.
Vest4
MVP
MPC
0.99
ClinPred
T
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at